<DOC>
	<DOCNO>NCT01274221</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy SPD489 compare placebo adolescent subject ( 13-17 year age inclusive ) ADHD analog classroom set base Permanent Product Measure Performance ( PERMP ) total score assess across 2 , 4 , 9 , 13 , 14 , 15 hour post-dose last day double-blind crossover period .</brief_summary>
	<brief_title>Safety Efficacy SPD489 Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>1 . Subject must male female , 1317 year age inclusive , time consent . 2 . The parent/LAR must available approximately 7:00 AM ( ±2 hour ) dispense dose investigational product study duration . 3 . Subject , female , must negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test negative urine pregnancy test agree comply applicable contraceptive requirement protocol . 4 . Subject meet Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIVTR ) criteria primary diagnosis ADHD base detailed psychiatric evaluation . 5 . Subject Attention Deficit/Hyperactivity Disorder Rating ScaleFourth Edition ( ADHDRSIV ) total score ≥28 . 6 . Subject function ageappropriate level intellectually . 7 . Subject able swallow capsule . 1 . Subject current , control ( medication prohibit study ) uncontrolled , comorbid psychiatric diagnosis significant symptom significant comorbid Axis II disorder significant Axis I disorder ( post traumatic stress disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , depressive anxiety disorder ) symptomatic manifestation , opinion examine clinician , contraindicate treatment SPD489 confound efficacy safety assessment . 2 . Subject documented history aggressive behavior serious enough preclude participation regular classroom activity , determine Investigator . Oppositional defiant disorder exclusionary . 3 . Subject currently consider suicide risk opinion Investigator , previously make suicide attempt , prior history , currently , demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator 4 . Subject underweight . 5 . Subject significantly overweight . 6 . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment conduct study might increase risk subject . 7 . Subject history seizure ( infantile febrile seizure ) , chronic current tic disorder , current diagnosis , and/or know family history Tourette 's Disorder . Subject history tic judge Investigator exclusionary . 8 . Subject known history symptomatic cardiovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place him/her increase vulnerability sympathomimetic effect stimulant drug . 9 . Subject know family history sudden cardiac death ventricular arrhythmia . 10 . Subject clinically significant electrocardiogram ( ECG ) clinically significant laboratory abnormality . 11 . Subject current abnormal thyroid function . Treatment stable dose thyroid medication least 3 month permit . 12 . Subject document allergy , hypersensitivity , intolerance amphetamine excipients investigational product . 13 . Subject fail respond 1 adequate course ( dose duration ) amphetamine therapy . 14 . Subject history suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR criterion . 15 . Subject positive urine drug result ( exception subject 's current stimulant therapy , ) . 16 . Subject take another investigational product take part clinical study within 30 day prior Screening visit . 17 . Subject previously screen study participate SPD489/NRP104 clinical study . 18 . Subject glaucoma . 19 . Subject take medication central nervous system ( CNS ) effect affect performance , sedate antihistamine decongestant sympathomimetics , monoamine oxidase inhibitor . Stable use bronchodilator inhaler exclusionary . 20 . Subject female pregnant lactating . 21 . Subject well control his/her current ADHD medication acceptable tolerability .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>